About Neural AI & Data Platforms
The Neural AI & Data Platforms category is part of the Brain Computer Interface market map, tracking 22 companies building in this segment. The most comprehensive brain-computer interface market map. Non-invasive and implantable BCI companies translating neural signals into digital commands — from Neuralink competitors to emerging neurotechnology startups. Curated by Hartmann Capital's venture research team.
Companies in Neural AI & Data Platforms
- MindMaze — Series A, $125M
- Ceribell — Series D, $125M
- Beacon Biosignals — Series A, $27M
- Rune Labs — Series B, $22M
- iMotions — Series B, $15M
- Elemind — Series A, $12M
- Arctop — Seed, $9M
- Piramidal — Seed, $6M
- Cogitat
- MindPortal
- Myndlift
- NeuroBrave
- Brainify.AI
- Altoida — Series B, $27M
- Linus Health — Series B, $55M
- BrainKey
- SPARK Neuro
- Bitsphi
- Qynapse — Series A, $20M
- BrainCheck — Series B, $15M
- Reneural
- Cambridge Cognition — Public
Frequently Asked Questions
- What companies are in the Neural AI & Data Platforms category?
- The Neural AI & Data Platforms category includes 22 companies: MindMaze, Ceribell, Beacon Biosignals, Rune Labs, iMotions, Elemind, Arctop, Piramidal, Cogitat, MindPortal, Myndlift, NeuroBrave, Brainify.AI, Altoida, Linus Health, BrainKey, SPARK Neuro, Bitsphi, Qynapse, BrainCheck, Reneural, Cambridge Cognition. This is part of the Brain Computer Interface market map maintained by Hartmann Capital.
- How many Neural AI & Data Platforms startups are tracked?
- Hartmann Capital tracks 22 companies in the Neural AI & Data Platforms segment of the Brain Computer Interface market map.
- What are the best funded Neural AI & Data Platforms companies?
- Top funded companies in Neural AI & Data Platforms include MindMaze ($125M), Ceribell ($125M), Linus Health ($55M), Beacon Biosignals ($27M), Altoida ($27M). Browse the full list in the Brain Computer Interface market map.
- How can I submit my startup?
- You can submit your startup for inclusion by visiting the submission page. Submissions are reviewed by Hartmann Capital's research team.